To improve accurate diagnosis and treatment of common malignant tumors and major infectious diseases in the respiratory system, we aim to establish a large medical database that includes standardized and structured clinical diagnosis and treatment information such as electronic medical records, image features, pathological features, and multi-omics information, and to develop a multi-modal data fusion-based technology system for individualized intelligent pathological diagnosis and therapeutic effect prediction using artificial intelligence technology.
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
The outcome of clinical diagnosis of suspected patients with lung cancer/pulmonary nodular (Benign/Malignant nodule).
Timeframe: 2021-2024
The outcome of clinical diagnosis of suspected patients with pulmonary tuberculosis (Positive/Negative).
Timeframe: 2021-2024
The outcome of clinical diagnosis of suspected patients with COVID-19 (Positive/Negative).
Timeframe: 2021-2024
Treatment response of anti-cancer therapy at first evaluation in patients with lung cancer/pulmonary nodules (CR, PR, PD, SD).
Timeframe: 2021-2024
Treatment response of anti-inflammation and antiviral therapy at first evaluation in patients with COVID-19 (effective/ineffective treatment).
Timeframe: 2021-2024
Treatment response of antituberculous bacilli and anti-inflammation therapy at first evaluation in patients with pulmonary tuberculosis.
Timeframe: 2021-2024
Progression free survival
Timeframe: 2021-2024
Overall survival
Timeframe: 2021-2024
Whole genome sequencing of blood samples
Timeframe: 2021-2024
Whole-genome sequencing of tissue samples
Timeframe: 2021-2024
Whole genome sequencing of exhaled air condensate samples
Timeframe: 2021-2024
Whole genome sequencing of urine samples
Timeframe: 2021-2024
Transcriptome sequencing of blood samples
Timeframe: 2021-2024
Transcriptome sequencing of tissue samples
Timeframe: 2021-2024
Transcriptome sequencing of exhaled air condensate samples
Timeframe: 2021-2024
Transcriptome sequencing of urine samples
Timeframe: 2021-2024
Metabolomics of blood samples
Timeframe: 2021-2024
Metabolomics of tissue samples
Timeframe: 2021-2024
Metabolomics of exhaled air condensate samples
Timeframe: 2021-2024
Metabolomics of urine samples
Timeframe: 2021-2024
Proteomics of blood samples
Timeframe: 2021-2024
Proteomics of tissue samples
Timeframe: 2021-2024
Proteomics of exhaled air condensate samples
Timeframe: 2021-2024
Proteomics of urine samples
Timeframe: 2021-2024